Joe and The Gene: A Mother's Perspective
By Lia Tremblay,
NPR
| 04. 09. 2020
Joe has my nose, his father’s eyes, and facial expressions that mirror those of his grandfathers. But the unexpected “misspelling” coiled up in his DNA has also given us a child we could never have imagined—and would never want to replace.
Seeing Thomas Hunt Morgan’s experiments with fruit flies in episode one of The Gene: An Intimate History took me right back to ninth grade biology. My entire class of 14-year-olds paired up to carefully sedate swarms of fruit flies and group them according to their physical characteristics. Then we matched them up for mating and inspected their offspring to see which eye colors, stripe patterns and wing shapes had passed down to the new generation.
For many years, that was the extent of my interest in genetics.
Then came Joe. The only child of my husband and me, Joe is 11 years old, laughs a lot and loves to dance. Like a lot of 11-year-olds, he spends too much time on his iPad, ignores our directions and dawdles over dinner.
But Joe is also very different from most of his peers. He speaks only a few words, learns new things at a leisurely pace, needs help with tasks like climbing steps and opening doors, and is about the size of a child half his age.
Like Susannah, the...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
